GENEMEDICS APP

GENEMEDICS NUTRITION

DHEA

Author: Dr. George Shanlikian, M.D.  |   Last Updated: November 28th, 2023

Share This Page

Dehydroepiandrosterone (DHEA), also known as androstenolone, is one of the most abundant circulating steroids in humans. Once secreted into the blood stream, the body converts DHEA into several other hormones such as testosterone and estrogen. Because of this vital function, DHEA is sometimes referred to as the “mother of all hormones” or “parent hormone”. DHEA is produced in the adrenal glands (small glands located on top of each kidney), the gonads (sex glands), and the brain.

Overall Health Benefits of DHEA

Aside from being a precursor to other important hormones, DHEA plays the following important functions:

  • Boosts immune function [1-16]
  • Decreases cholesterol [17-22]
  • Decreases formation of fatty deposits in the brain and blood vessels [23-30]
  • Enhances mood [31-54]
  • Improves cognitive function [55-60]
  • Improves quality of life [61-68]
  • Improves stress response [69-77]
  • Increases libido [78-83]
  • Lowers blood sugar [84-87]
  • Maintains healthy bones and prevents osteoporosis [88-97]
  • Maintains healthy heart [98-104]
  • Promotes weight loss [105-107]

DHEA in Women

Touted as the “super hormone”, DHEA plays several important functions in women:

  • Improves menopausal symptoms [108-117]
  • Improves fertility [118-132]
  • Treats low libido [133-138]
  • Improves skin quality [139-141]

DHEA in Men

In men, this powerful hormone works in numerous ways:

  • Increases muscle mass and strength [142-146]
  • Reduces fat mass [147-148]
  • Helps with addressing erectile dysfunction [149-153]

DHEA Deficiency

The levels of DHEA tend to gradually deteriorate with age. In addition, certain factors such as lifestyle, diet, emotional health, and stress levels can affect DHEA levels. It is a known fact that the level of this hormone start to decline after the age of 30, causing a wide array of negative health implications. Typical symptoms of DHEA deficiency (adrenal insufficiency) include:

  • Allergies
  • Decreased bone mineral density
  • Decreased sex drive
  • Depression
  • Dry eyes, skin, and hair
  • Elevated anxiety and stress levels
  • Erectile dysfunction
  • Extreme fatigue
  • Heightened sound sensitivity
  • Joint pain
  • Loss of muscle mass
  • Loss of pubic hair
  • Low immunity
  • Memory problems
  • Mood swings
  • Painful sexual intercourse
  • Sleeping difficulties
  • Weight gain/Obesity

If you are experiencing one or more of these symptoms, consult immediately with a qualified hormone replacement therapy doctor to assess your DHEA levels and come up with an appropriate medical management that is tailored to your needs.

Proven Health Benefits of DHEA Replacement Therapy

DHEA replacement therapy has gained worldwide attention over recent years. An overwhelming body of clinical research supports the significant beneficial effects of DHEA administration in patients with complete DHEA deficiency. Whether taken orally in the form of tablets or capsules, or given in the form of injections or applied directly to the skin, studies show that this “super hormone” can benefit almost every organ system in the body and can help combat a wide array of fatal diseases.

Fights Inflammation

Inflammation is the root cause of most diseases and is strongly linked with almost all age-related health problems. DHEA’s potent anti-inflammatory properties can help ward off various inflammatory disorders associated with advancing age and improve overall quality of life. Several research studies confirm the anti-inflammatory effects of DHEA:

  1. DHEA protects human neurons (nerve cells) from HIV-associated inflammation and prevents degeneration. [154-155]
  2. In patients with chronic inflammatory diseases, DHEA replacement therapy reduces the levels of inflammatory markers. [156]
  3. In patients with asthma and allergies, DHEA attenuates T helper 2 allergic inflammation and reduces airway hyperreactivity. [157]
  4. In patients with inflammatory bowel disease, DHEA restrains intestinal inflammation by modifying white blood cell activity and balancing the exacerbated immune responses. [158]
  5. In patients with Crohn’s disease and ulcerative colitis, DHEA decreases disease activity without any adverse side effects. [159]
  6. In patients with systemic lupus erythematosus (SLE), a chronic inflammatory disease, DHEA administration reduces dose of prednisone (thus avoiding its adverse effects) while also improving symptoms. [160]
  7. DHEA stops inflammation and restores normal colon length in mouse models of inflammatory bowel disease. [161]
  8. In mice, DHEA administration decreases the systemic inflammatory response induced by bilateral femoral fracture. [162]
  9. In animal models, DHEA suppresses experimental brain inflammation by reducing the levels of inflammatory substances. [163-168]

Improves Bone Strength and Quality

DHEA possesses potent anti-aging properties that help protect against loss of bone mineral density and strength, thereby reducing the risk of fractures and osteoporosis. Apart from aging, bone loss occur at higher rates in people with hormonal imbalances, poor eating habits, unhealthy lifestyle, and those with medical conditions that affect bone quality. As the “mother of all hormones”, evidence suggests that DHEA replacement therapy improves bone production and quality by boosting the production of other hormones necessary for bone production:

  1. In elderly men and women, DHEA replacement therapy significantly increases bone mineral density and the levels of the bone-boosting hormones insulin-like growth factor 1 and testosterone. [169-172]
  2. In women, 12 months of DHEA treatment increases bone mineral density of the lumbar spine as well as estrogen levels. [173-174]
  3. In men and women with low levels of DHEA due to disease, short duration of DHEA treatment improves bone mineral density and bone metabolism. [175-180]
  4. In older healthy individuals, DHEA prevents bone loss and osteoporosis. [181-182]
  5. DHEA acts protectively against osteoporosis by increasing bone-forming cells known as osteoblasts. [183]
  6. In older women, DHEA supplementation improves bone mineral density when co-administered with vitamin D and calcium. [184]
  7. In older adults, long-term (12–24 months) DHEA replacement therapy significantly increases or preserves bone mineral density while preventing bone breakdown. [185-188]
  8. In young adults, DHEA decreases bone breakdown and increases bone formation without any adverse side effects. [189]
  9. In young women with anorexia nervosa (eating disorder characterized by fear of gaining weight and strong desire to be thin), DHEA treatment significantly increases bone mineral density of both hip and spine. [190]
  10. In postmenopausal women, higher DHEA levels are associated with lesser bone loss. [191]
  11. In postmenopausal women, DHEA treatment significantly increases bone mineral density as well as blood levels of osteocalcin, a marker of bone formation. [192]

Maintains Heart Health

DHEA appears to play a major role in cardiovascular function and deficiency in this vital hormone may compromise heart health. In fact several high quality studies found a strong link between DHEA deficiency and higher incidence of heart diseases in both men and women. [193-207] This suggests that replacing DHEA to youthful levels can help boost heart health and prevent various fatal heart diseases. A number of clinical trials support the beneficial effects of DHEA replacement therapy on the cardiovascular system:

  1. In patients with coronary heart disease, DHEA inhibits human platelet aggregation and dissolves blood clots. [208]
  2. In patients with cardiovascular disease, DHEA relaxes the blood vessels of the heart, thereby improving blood flow and function. [209]
  3. In patients with coronary heart disease, DHEA replacement therapy significantly decreases the levels of fibrinogen, a protein associated with blood clotting. [210]
  4. In patients with cardiovascular disease, higher DHEA levels are associated with better prognosis. [211]
  5. In postmenopausal women, long-term treatment with DHEA lowers cardiovascular risk by improving insulin sensitivity and cholesterol levels. [212-213]

Improves Brain Function

As a nootropic agent or cognitive-enhancer, DHEA is among the most important neurosteroids. Neurosteroids are steroids synthesized within the brain that help maintain the functions of nerve cells. There is strong scientific evidence that DHEA supplementation can help boost brain function in the elderly as well as those with cognitive impairments related to various brain problems:

  1. In women, DHEA supplementation improves memory by stimulating neurons and inhibiting the stress hormone cortisol. [214]
  2. In patients with depression and anxiety, DHEA enhances emotional regulation of memory by improving the function of the hippocampus (memory center of the brain). [215-216]
  3. In young adults, DHEA improves visual processing. [217]
  4. In women, DHEA supplementation improves working memory, attention and verbal fluency. [218]
  5. In elderly men and women, DHEA supplementation significantly improves executive function and memory. [219]
  6. In men, DHEA replacement therapy at a dose of 300 mg daily improves memory recollection and mood and decreases cortisol levels. [220]
  7. In older women with mild to moderate cognitive impairment, oral DHEA supplementation at a dose of 25 mg daily for 6 months improves cognition and activities of daily living. [221]
  8. In rat models of Alzheimer’s disease, DHEA supplementation reduces symptoms and improves memory. [222]

Increases Pregnancy Rate

For women who want to increase their chances of getting pregnant, DHEA supplementation can help. In fact, DHEA supplements are actually prescribed by doctors in women with diminished ovarian reserve (DOR), a condition in which the ovaries lose their reproductive potential. Several clinical trials assessing the beneficial effects of DHEA replacement therapy on pregnancy rate have shown positive outcomes for many women:

  1. In young women who do not respond well to in vitro fertilization (IVF), DHEA supplementation at dose of 25 mg three times daily for at least 12 weeks significantly increases spontaneous pregnancy rate. [223]
  2. In women with lower fertility rates, DHEA improves ovarian function, increases pregnancy chances and lowers miscarriage rates. [224]
  3. DHEA significantly reduces miscarriages in women by preventing aneuploidy (presence of an abnormal number of chromosomes in a cell). [225-229]
  4. In women with lower fertility rates, DHEA supplementation improves pregnancy rate by increasing the number and quality of oocyte (egg cell) and embryo. [230-232]
  5. In women with hormonal imbalances, DHEA supplementation for at least 3 months is associated with spontaneous and treatment-induced pregnancies. [233-234]
  6. In women with DOR, DHEA replacement therapy increases the levels of Anti-Mullerian Hormone (AMH), an indicator of good ovarian reserve. [235]

Promotes Weight Loss

While proper diet and regular exercise are important factors involved in maintaining a healthy weight, hormones like DHEA play an important role too. This “super hormone” boosts the body’s natural ability to utilize energy reserves and burn fat, two metabolic processes that gradually decline with advancing age. Studies show that DHEA replacement therapy promotes weight loss, thus reducing one’s risk of developing obesity-related diseases:

  1. In obese men, DHEA supplementation reduces body mass index (BMI). [236]
  2. In overweight men and women, DHEA supplementation promotes weight loss by increasing metabolic rate. [237]
  3. In overweight adults, DHEA supplementation is associated with a three-fold decrease in body weight and fat mass. [238]
  4. In young athletes, DHEA reduces BMI, waist-to-hip ratio (WHR) and body fat while increasing testosterone and estrogen levels. [239]
  5. In age-advanced men, 100 mg daily dose of DHEA decreases fat body mass. [240]

Lowers Blood Sugar Levels

Acquiring more DHEA can help combat diabetes and other diseases linked with high blood sugar levels. Results of human studies assessing the anti-diabetic effects of DHEA suggest that it can protect against insulin resistance induced by aging and unhealthy lifestyle:

  1. In older men and women, 6 months of DHEA replacement therapy improves insulin action, thereby reducing blood sugar levels. [241]
  2. In women with stress hormone deficiency, DHEA replacement therapy lowers blood sugar levels by improving the body’s response to insulin. [242]
  3. In older men and women, DHEA treatment at a dose of 50 mg daily for 6 months reduces adiposity while improving blood sugar levels. [243]
  4. In middle-aged and elderly men and women, higher DHEA levels are associated with a lower risk of type 2 diabetes. [244]
  5. In older men and women, DHEA prevents insulin resistance by reducing the levels of inflammatory cytokines such as IL-6 and TNFα. [245-250]
  6. DHEA reverses insulin resistance by activating peroxisome proliferator-activated receptor (PPARα), a group of proteins that play a role in the metabolism of carbohydrates, lipids, and proteins. [251-261]
  7. Another mechanism by which DHEA improves insulin action is by improving the activation of phosphatidyl inositol 3-kinase and Akt/PkB pathway, both of which play a key role in blood sugar metabolism. [262-264]

Improves Sleep Quality

Troublesome and frustrating, sleeping problems associated with aging can negatively impact one’s quality of life. Hormonal imbalance during this stage is thought to affect sleep quality, resulting in lack of sleep and extreme fatigue. Specifically, the age-related decline in various hormones such as testosterone, estrogen, and DHEA contributes to insomnia. Because DHEA is a precursor to several other important hormones in the body, researchers believe that restoring DHEA to youthful levels can help improve sleep quality. A number of clinical trials support the beneficial effects of DHEA on sleep:

  1. In men, a single dose of DHEA (500 mg) induces a significant increase in rapid eye movement (REM), one of the deepest stages of sleep. [265]
  2. In healthy postmenopausal women, oral DHEA administration at a dose of 50 mg daily for 3 weeks enhances sleep quality. [266]

Improves Muscle Mass and Strength

Regular exercises along with proper diet are known to increase muscle mass and strength. However, not all older individuals may benefit from these strategies due to reduced activity levels and slower metabolism. Interestingly, there is increasing evidence that DHEA supplementation can aid in improving muscle mass and strength especially in the older population. Studies show that DHEA replacement therapy is beneficial in both older men and women:

  1. In elderly men and women, DHEA replacement therapy enhances the effect of weightlifting training on muscle strength. [267]
  2. In postmenopausal women, DHEA supplementation improves muscle strength and function. [268]
  3. In elderly men and women, DHEA supplementation improves muscle mass and strength as well as gait speed. [269]
  4. In healthy non-obese age-advanced (50-65 years of age) men, a daily oral 100 mg dose of DHEA for 6 months increases knee muscle strength as well as lumbar back strength. [270]
  5. DHEA also helps protect against muscle wasting by preventing cell oxidation and cell death. [271]
  6. In frail older women, DHEA supplementation improves lower extremity strength and physical function. [272]

Relieves Menopausal Symptoms

Menopausal women often experience debilitating symptoms that ruin their quality of life, including hot flushes, sleeping difficulties, fatigue, sexual dysfunction, headaches, body pains, and mood swings.  Researchers believe that menopause and low DHEA levels go hand in hand, and by restoring DHEA to youthful levels through hormone replacement therapy, menopausal women can significantly experience relief from these unpleasant symptoms. A number of high quality studies conducted in menopausal women support the benefits of DHEA:

  1. Intravaginal administration of DHEA improves vaginal health and lessens pain during sexual intercourse. [273]
  2. In postmenopausal women, intravaginal administration of DHEA prevents vaginal atrophy (thinning, drying and inflammation of the vaginal walls). [274]
  3. Daily intravaginal administration of DHEA causes highly statistically significant improvements in vaginal dryness, vaginal pH acidity, and pain during sexual activity. [275-277]
  4. In menopausal women, four weeks of DHEA therapy decreases hot flushes by 50%. [278]
  5. In early and late postmenopausal women, DHEA replacement therapy for 3-6 months improves hot flushes and night sweats. [279]
  6. In early postmenopausal women, DHEA replacement therapy improves sexual function and frequency of sexual intercourse. [280]

Treats Erectile Dysfunction (ED)

DHEA doesn’t only treat sexual dysfunction in women, but also in men with ED. As a building block for testosterone, the key male sex hormone, DHEA may be able to ramp up sexual power in men with ED. Strong scientific evidence supports the beneficial effects of DHEA on this condition:

  1. In men with ED, DHEA therapy at an oral dose of 50 mg daily for 6 months improves scores in International Index of Erectile Function (IIEF). [281]
  2. In patients with ED who have hypertension, DHEA treatment is associated with statistically higher mean scores in IIEF. [282]
  3. In men with ED, DHEA supplementation improves sexual interest, arousal, orgasm and sexual frequency. [283]
  4. In men with ED caused by chronic prostate inflammation, DHEA supplementation significantly improves sexual function. [284]

Fights Cancer

DHEA does not only have anti-aging capability but it also has potent anti-cancer properties. There is strong scientific evidence that this hormone is capable of destroying various cancer cell types, thereby preventing its spread in different body parts (metastasis). Results from numerous studies show that DHEA fights cancer through various mechanisms:

  1. In patients with colon cancer, DHEA prevents the metastatic progression of colon cancer cells by targeting the prenylation pathway, a process that contributes to the spread of cancer cells. [285]
  2. In cancer patients, DHEA administration at a dose of 25-50 mg daily induces significant normalization of abnormal cancer parameters. [286]
  3. DHEA inhibits the growth and reproduction of different human breast cancer cell lines by inhibiting the production of inflammatory substances and proteins related with cell migration and metastasis. [287-288]
  4. In postmenopausal women, DHEA inhibits the growth of breast cancer cells. [289]
  5. In patients with advanced prostate cancer who are unresponsive to chemotherapy and other standard treatment regimens, DHEA significantly improves symptoms. [290]
  6. Dietary supplementation with 0.6% DHEA significantly inhibits pancreatic cancer cell growth. [291]
  7. DHEA inhibits the growth, reproduction, and migration of human uterine cervical cancers by inducing programmed cell death. [292-293]

Boosts Immune Function

The age-related decline in DHEA levels is believed to contribute to various medical conditions, including impairment of immune function. This predisposes older individuals to a wide array of fatal diseases like autoimmune disorders and inflammatory conditions. Research suggests that DHEA supplementation may help improve symptoms and even prevent immune system-related disorders by boosting immune function via several different mechanisms:

  1. In patients with systemic lupus erythematosus (SLE), DHEA significantly reduces symptoms and improves health related quality of life. [294-306]
  2. In patients with tuberculosis, DHEA helps relieve symptoms by clearing bacteria and preventing tissue damage. [307]
  3. DHEA improves immune function by reducing the levels of the stress hormone cortisol. [308]
  4. DHEA has strong antiviral, antibacterial, and anti-parasitic properties capable of protecting against a variety of lethal infections. [309-310]
  5. In age-advanced men with low DHEA levels, administration of oral DHEA at a daily dose of 50 mg significantly activates immune function by increasing the levels of insulin-like growth factor 1 (IGF-1), a hormone that has immune-modulating effects. [311]
  6. DHEA improves immune function by regulating the production of pro-inflammatory cytokines such as IL-2, IL-1, IL-6 and TNFα. [312-319]
  7. DHEA is metabolized to other sex hormones such as estrogen and testosterone, both of which regulate immune cell development and function. [320-324]
  8. In elderly men and women, DHEA boosts immune function by increasing the production of immune system cells such as CD4+ T cells. [325-332]
  9. DHEA mediates its immune-boosting effects by suppressing the mitogen-activated protein kinases (MAPK) pathway in activated lymphocytes (white blood cells). [333] An increase in this pathway is associated with compromised immune function. [334]
  10. DHEA improves immune function by enhancing natural killer cell activity. [335]
  11. DHEA supplementation is used to enhance the antibody response to tetanus and influenza vaccines. [336-338]
  12. In patients with asthma, DHEA reduces allergic inflammatory airway reactions, thereby improving symptoms. [339]

Wards off Depression and Improves Mood

Low mood and depression are among the most common psychological symptoms associated with old age. There is increasing evidence that age-related DHEA deficiency is strongly linked with depression, [340-341] suggesting that DHEA replacement therapy can be beneficial in improving depressive symptoms as well as quality of life. Results from various human studies assessing the beneficial effects of DHEA on mood show that this hormone can help maintain a positive outlook, energy and motivation:

  1. In older men and women (40-70 years), DHEA administration at 50 mg daily improves energy levels and ability to handle stress. [342]
  2. In patients with depression that is mild or resistant to conventional therapy, DHEA supplementation improves depressive symptoms. [343]
  3. In middle-aged and elderly patients with major depression and low DHEA levels, treatment with DHEA at 30-90 mg daily for 6 months significantly improves depression ratings and memory performance while increasing DHEA levels. [344]
  4. In men, DHEA administration reduces activity in brain regions associated with generation of negative emotion, thereby improving mood. [345]
  5. In patients with major depressive disorder, DHEA administration is associated with significant reduction in depressive symptoms. [346-348]
  6. In men, DHEA administration increases activity in the anterior cingulate cortex, a region in the brain involved with emotion formation. [349]
  7. DHEA also modulates dopamine and serotonin release in the brain, both of which play a key role in emotion regulation and episodic memory. [350]
  8. In patients with anxiety disorder, DHEA administration improves the function of the amygdala, a brain region that plays a key role in the processing of emotions. [351]
  9. In patients with post-traumatic stress disorder (PTSD), DHEA administration is positively associated with adaptive responses to stress and symptom improvement and coping. [352-353]
  10. In depressed and nondepressed men and women, DHEA administration has mood-elevating effects. [354-357]
  11. In women with adrenal insufficiency (lack of steroid hormones, primarily cortisol), DHEA significantly improves overall well-being as well as scores for depression and anxiety. [358-360]
  12. In patients with depression, low-dose topical DHEA treatment improves subjective measures of fatigue, depression, and vitality. [361]

Improves Cholesterol Levels

Cholesterol is required for DHEA production. In fact, the process by which DHEA is produced starts when cholesterol enters the “powerhouse” of cells known as mitochondria. [362] Researchers believe that this process may help lower cholesterol and increase DHEA levels in the body, thereby boosting overall health. Results from several studies support the beneficial effects of DHEA supplementation on cholesterol levels:

  1. In overweight individuals, higher DHEA levels are associated with lower cholesterol levels. [363]
  2. In older women with frailty characteristics, DHEA supplementation improves total cholesterol and low-density lipoprotein (LDL) levels. [364]
  3. In men aged 41-60 years, DHEA therapy at a dose of 150 mg daily for 40 days reduces total cholesterol levels. [365]
  4. In postmenopausal women, DHEA supplementation has favourable effect on cholesterol levels. [366]

Reduces Wrinkles and other Signs of Skin Aging

DHEA can reduce wrinkles and other skin imperfections associated with aging. Studies show that this hormone exerts its anti-aging effect through various mechanisms:

  1. In postmenopausal women aged 60-65 years, skin application of DHEA cream twice daily for 13 weeks improves skin health and appearance by increasing the levels of collagen, a protein that makes the skin radiant and younger-looking. [367]
  2. In postmenopausal women, skin application of DHEA cream is associated with greater procollagen and collagen production. [368-370]
  3. In older women, oral DHEA supplementation at a dose of 50 mg daily for 1 year improves skin hydration, skin thickness and oil production, and reduces skin pigmentation. [371]
  4. In patients with skin atrophy (skin thinning), oral DHEA prevents frequent skin tearing. [372]
  5. In postmenopausal women, skin application of DHEA cream reduces wrinkles and blemishes. [373]
  6. In postmenopausal women, DHEA decreases the production of the collagenase enzymes that destroy collagen. [374]
  7. DHEA also decreases the production of genes associated with the formation of calluses and rough skin in postmenopausal women. [375]

Prevents Stroke

Stroke is one of the most deadly diseases worldwide. Interestingly, aside from diet and lifestyle, studies show that low DHEA levels are strongly associated with increased risk of stroke and related death. [376] Fortunately, increasing DHEA levels through replacement therapy can significantly prevent stroke, according to studies:

  1. DHEA prevents the death of healthy cells in the brain by inhibiting inflammatory processes. [377]
  2. In post-stroke patients, DHEA supplementation can improve functional outcome. [378]
  3. DHEA protects nerve cells in the brain from injury. [379]

References:

  1. Khorram O, Vu L, Yen SS. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. The journals of gerontology. Series A, Biological sciences and medical sciences. 1997; 52(1):M1-7.
  2. Buford TW, Willoughby DS. Impact of DHEA(S) and cortisol on immune function in aging: a brief review. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2008; 33(3):429-33.
  3. Catania RA, Angele MK, Ayala A, Cioffi WG, Bland KI, Chaudry IH. Dehydroepiandrosterone restores immune function following trauma-haemorrhage by a direct effect on T lymphocytes. Cytokine. 1999; 11(6):443-50.
  4. Loria RM, Padgett DA. Control of the immune response by DHEA and its metabolites. Rinsho byori. The Japanese journal of clinical pathology. 1998; 46(6):505-17.
  5. Chen CC, Parker CR. Adrenal androgens and the immune system. Seminars in reproductive medicine. 2004; 22(4):369-77.
  6. Ledochowski M, Murr C, Jäger M, Fuchs D. Dehydroepiandrosterone, ageing and immune activation. Experimental gerontology. 2001; 36(10):1739-47.
  7. Heffner KL. Neuroendocrine effects of stress on immunity in the elderly: implications for inflammatory disease. Immunology and allergy clinics of North America. 2011; 31(1):95-108.
  8. Butcher SK, Lord JM. Stress responses and innate immunity: aging as a contributory factor. Aging cell. 2004; 3(4):151-60.
  9. Loria RM, Padgett DA, Huynh PN. Regulation of the immune response by dehydroepiandrosterone and its metabolites. The Journal of endocrinology. 1996; 150 Suppl:S209-20.
  10. Oberbeck R, Dahlweid M, Koch R, et al. Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Critical care medicine. 2001; 29(2):380-4.
  11. Morfin R, Lafaye P, Cotillon AC, Nato F, Chmielewski V, Pompon D. 7 alpha-hydroxy-dehydroepiandrosterone and immune response. Annals of the New York Academy of Sciences. 2000; 917:971-82.
  12. Brazão V, Santello FH, Caetano LC, Del Vecchio Filipin M, Toldo MP, do Prado JC. Immunomodulatory effects of zinc and DHEA on the Th-1 immune response in rats infected with Trypanosoma cruzi. Immunobiology. 2010; 215(5):427-34.
  13. Araneo B, Daynes R. Dehydroepiandrosterone functions as more than an antiglucocorticoid in preserving immunocompetence after thermal injury. Endocrinology. 1995; 136(2):393-401.
  14. Sawalha AH, Kovats S. Dehydroepiandrosterone in systemic lupus erythematosus. Current rheumatology reports. 2008;10(4):286-291.
  15. Alexaki VI, Fodelianaki G, Neuwirth A, et al. DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1/2-CREB-Jmjd3 pathway. Molecular psychiatry. 2017.
  16. Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertility and sterility. 2001; 76(2):241-8.
  17. Miller WL. Androgen biosynthesis from cholesterol to DHEA. Molecular and cellular endocrinology. 2002; 198(1-2):7-14.
  18. Kritchevsky D, Tepper SA, Klurfeld DM, Schwartz AG. Influence of dehydroepiandrosterone (DHEA) on cholesterol metabolism in rats. Pharmacological research communications. 1983; 15(9):797-803.
  19. Miller WL. Early steps in androgen biosynthesis: from cholesterol to DHEA. Bailliere’s clinical endocrinology and metabolism. 1998; 12(1):67-81.
  20. Miller WL. Disorders of androgen synthesis–from cholesterol to dehydroepiandrosterone. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2005; 14 Suppl 1:58-68.
  21. Jedrzejuk D, Medras M, Milewicz A, Demissie M. Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism. The aging male : the official journal of the International Society for the Study of the Aging Male. 2003; 6(3):151-6.
  22. Boxer RS, Kleppinger A, Brindisi J, Feinn R, Burleson JA, Kenny AM. Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics. Age and Ageing. 2010;39(4):451-458. doi:10.1093/ageing/afq043.
  23. Hayashi T, Esaki T, Muto E, et al. Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide. Arteriosclerosis, thrombosis, and vascular biology. 2000; 20(3):782-92.
  24. Samaras N, Samaras D, Frangos E, Forster A, Philippe J. A Review of Age-Related Dehydroepiandrosterone Decline and Its Association with Well-Known Geriatric Syndromes: Is Treatment Beneficial? Rejuvenation Research. 2013;16(4):285-294. doi:10.1089/rej.2013.1425.
  25. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocrine reviews. 2003; 24(2):183-217.
  26. Jiménez MC, Sun Q, Schürks M, et al. Low dehydroepiandrosterone sulphate is associated with increased risk of ischemic stroke among women: DHEAS and Risk of Ischemic Stroke in Women. Stroke; a journal of cerebral circulation. 2013;44(7):10.1161/STROKEAHA.111.000485. doi:10.1161/STROKEAHA.111.000485.
  27. Mannic T, Viguie J, Rossier MF. In vivo and in vitro evidences of dehydroepiandrosterone protective role on the cardiovascular system. International journal of endocrinology and metabolism. 2015; 13(2):e24660.
  28. Available at https://academic.oup.com/aje/article/157/1/25/66203.
  29. Corona G, Rastrelli G, Giagulli VA, et al. Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-controlled trials. The Journal of clinical endocrinology and metabolism. 2013; 98(9):3615-26.
  30. Golden SH, Maguire A, Ding J, et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. American journal of epidemiology. 2002; 155(5):437-45.
  31. Pluchino N, Drakopoulos P, Bianchi-Demicheli F, Wenger JM, Petignat P, Genazzani AR. Neurobiology of DHEA and effects on sexuality, mood and cognition. The Journal of steroid biochemistry and molecular biology. 2015; 145:273-80.
  32. Sripada, R. K., Marx, C. E., King, A. P., Rajaram, N., Garfinkel, S. N., Abelson, J. L., & Liberzon, I. (2013). DHEA Enhances Emotion Regulation Neurocircuits and Modulates Memory for Emotional Stimuli. Neuropsychopharmacology, 38(9), 1798–1807. http://doi.org/10.1038/npp.2013.79
  33. Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R. DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology. 2000; 25(1):53-68.
  34. Young EA. DHEA: mood, memory, and aging. Biological psychiatry. 1999; 45(12):1531-2.
  35. Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double blind trial. The Journal of clinical endocrinology and metabolism. 2000; 85(12):4650-6.
  36. Peixoto C, Devicari Cheda JN, Nardi AE, Veras AB, Cardoso A. The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illnesses: a systematic review. Current drug targets. 2014; 15(9):901-14.
  37. Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biological psychiatry. 1997; 41(3):311-8.
  38. Sripada RK, Marx CE, King AP, et al. DHEA Enhances Emotion Regulation Neurocircuits and Modulates Memory for Emotional Stimuli. Neuropsychopharmacology. 2013;38(9):1798-1807. doi:10.1038/npp.2013.79.
  39. Wolkowitz OM, Reus VI, Roberts E, et al. Antidepressant and cognition-enhancing effects of DHEA in major depression. Annals of the New York Academy of Sciences. 1995; 774:337-9.
  40. Peixoto C, Devicari Cheda JN, Nardi AE, Barciela Veras A, Cardoso A. The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illness: a systematic review. Current Drug Targets 2014; 15(9): 901.
  41. Markopoulou K, Papadopoulos A, Juruena MF, Poon L, Pariante CM, Cleare AJ. The ratio of cortisol/DHEA in treatment resistant depression. Psychoneuroendocrinology. 2009; 34(1):19-26.
  42. Załuska M, Janota B. [Dehydroepiandrosteron (DHEA) in the mechanisms of stress and depression]. Psychiatria polska. ; 43(3):263-74.
  43. Glick R, Jimenez X. P02.62. DHEA augmentation strategy for treatment of fatigue and depression: a case presentation. BMC Complementary and Alternative Medicine. 2012;12(Suppl 1):P118. doi:10.1186/1472-6882-12-S1-P118.
  44. Angold A. Adolescent depression, cortisol and DHEA. Psychological medicine. 2003; 33(4):573-81.
  45. Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH. Neurobiological and Neuropsychiatric Effects of Dehydroepiandrosterone (DHEA) and DHEA Sulfate (DHEAS). Frontiers in neuroendocrinology. 2009;30(1):65-91. doi:10.1016/j.yfrne.2008.11.002.
  46. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. The American journal of psychiatry. 1999; 156(4):646-9.
  47. Gallagher P, Young A. Cortisol/DHEA ratios in depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2002; 26(3):410.
  48. Hsiao CC. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression. Psychoneuroendocrinology. 2006; 31(7):839-46.
  49. Kritz-Silverstein D, von Mühlen D, Laughlin GA, Bettencourt R. Effects of Dehydroepiandrosterone Supplementation on Cognitive Function and Quality of Life: The DHEA and Well-Ness (DAWN) Trial. Journal of the American Geriatrics Society. 2008;56(7):1292-1298. doi:10.1111/j.1532-5415.2008.01768.x.
  50. Maayan R, Morad O, Dorfman P, Overstreet DH, Weizman A, Yadid G. The involvement of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) in blocking the therapeutic effect of electroconvulsive shocks in an animal model of depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2005; 15(3):253-62.
  51. Souza-Teodoro LH, de Oliveira C, Walters K, Carvalho LA. Higher serum dehydroepiandrosterone sulfate protects against the onset of depression in the elderly: Findings from the English Longitudinal Study of Aging (ELSA). Psychoneuroendocrinology. 2016;64:40-46. doi:10.1016/j.psyneuen.2015.11.005.
  52. Kurita H, Maeshima H, Kida S, et al. Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (S) levels in medicated patients with major depressive disorder compared with controls. Journal of affective disorders. 2013; 146(2):205-12.
  53. DHEA: over-the-counter antidote for depression. Non-prescription hormonal supplement can help relieve minor and major depression in middle age. Health news (Waltham, Mass.). 2005; 11(6):12-3.
  54. Davis SR, Shah SM, McKenzie DP, Kulkarni J, Davison SL, Bell RJ. Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. The Journal of clinical endocrinology and metabolism. 2008; 93(3):801-8.
  55. Huppert FA, Van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function . The Cochrane database of systematic reviews. 2001.
  56. Grimley Evans J, Malouf R, Huppert F, van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. The Cochrane database of systematic reviews. 2006.
  57. Huppert FA, Van Niekerk JK, Herbert J. Dehydroepiandrosterone (DHEA) supplementation for cognition and well-being. The Cochrane database of systematic reviews. 2000.
  58. De Menezes KJ, Peixoto C, Nardi AE, Carta MG, Machado S, Veras AB. Dehydroepiandrosterone, Its Sulfate and Cognitive Functions. Clinical Practice and Epidemiology in Mental Health : CP & EMH. 2016;12:24-37. doi:10.2174/1745017901612010024.
  59. Maggio M, De Vita F, Fisichella A, et al. DHEA and cognitive function in the elderly. The Journal of steroid biochemistry and molecular biology. 2015; 145:281-92.
  60. Pluchino N, Drakopoulos P, Bianchi-Demicheli F, Wenger JM, Petignat P, Genazzani AR. Neurobiology of DHEA and effects on sexuality, mood and cognition. The Journal of steroid biochemistry and molecular biology. 2015; 145:273-80.
  61. Kritz-Silverstein D, von Mühlen D, Laughlin GA, Bettencourt R. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial. Journal of the American Geriatrics Society. 2008; 56(7):1292-8.
  62. Heald AH, Walther A, Davis JRE, et al. No Difference in Mood and Quality of Life in DHEA-S Deficient Adults with Addison’s Disease vs. Type 2 Diabetes Patients with Normal DHEA-S Levels: Implications for Management of These Conditions. Frontiers in psychology. 2017; 8:764.
  63. Nordmark G, Bengtsson C, Larsson A, Karlsson FA, Sturfelt G, Rönnblom L. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005; 38(7):531-40.
  64. Bovenberg SA, van Uum SH, Hermus AR. Dehydroepiandrosterone administration in humans: evidence based? The Netherlands journal of medicine. 2005; 63(8):300-4.
  65. Elraiyah T, Sonbol MB, Wang Z, et al. Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. The Journal of clinical endocrinology and metabolism. 2014; 99(10):3536-42.
  66. Eden JA. DHEA replacement for postmenopausal women: placebo or panacea? Climacteric : the journal of the International Menopause Society. 2015; 18(4):439-40.
  67. Lang K, Burger-Stritt S, Hahner S. Is DHEA replacement beneficial in chronic adrenal failure? Best practice & research. Clinical endocrinology & metabolism. 2015; 29(1):25-32.
  68. Virkki LM, Porola P, Forsblad-d’Elia H, Valtysdottir S, Solovieva SA, Konttinen YT. Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sjögren’s syndrome. Arthritis care & research. 2010; 62(1):118-24.
  69. Boudarene M, Legros JJ, Timsit-Berthier M. [Study of the stress response: role of anxiety, cortisol and DHEAs]. L’Encephale. ; 28(2):139-46.
  70. Lennartsson AK, Kushnir MM, Bergquist J, Jonsdottir IH. DHEA and DHEA-S response to acute psychosocial stress in healthy men and women. Biological psychology. 2012; 90(2):143-9.
  71. Maninger N, Capitanio JP, Mason WA, Ruys JD, Mendoza SP. Acute and chronic stress increase DHEAS concentrations in rhesus monkeys. Psychoneuroendocrinology. 2010;35(7):1055-1062. doi:10.1016/j.psyneuen.2010.01.006.
  72. Kamin HS, Kertes DA. Cortisol and DHEA in development and psychopathology. Hormones and behavior. 2017; 89:69-85.
  73. Lennartsson AK, Theorell T, Rockwood AL, Kushnir MM, Jonsdottir IH. Perceived stress at work is associated with lower levels of DHEA-S. PloS one. 2013; 8(8):e72460.
  74. Qiao S, Li X, Zilioli S, et al. Hair Measurements of Cortisol, DHEA, and DHEA to Cortisol Ratio as Biomarkers of Chronic Stress among People Living with HIV in China: Known-Group Validation. Nater UM, ed. PLoS ONE. 2017;12(1):e0169827. doi:10.1371/journal.pone.0169827.
  75. Phillips AC, Carroll D, Gale CR, Lord JM, Arlt W, Batty GD. Cortisol, DHEAS, their ratio and the metabolic syndrome: evidence from the Vietnam Experience Study. European journal of endocrinology. 2010; 162(5):919-23.
  76. Phillips AC, Carroll D, Gale CR, Lord JM, Arlt W, Batty GD. Cortisol, DHEAS, their ratio and the metabolic syndrome: evidence from the Vietnam Experience Study. European journal of endocrinology. 2010; 162(5):919-23.
  77. Goodyer IM, Park RJ, Netherton CM, Herbert J. Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology. The British journal of psychiatry : the journal of mental science. 2001; 179:243-9.
  78. Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and wellbeing. Human reproduction update. ; 13(3):239-48.
  79. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. The journal of sexual medicine. 2009; 6(9):2579-90.
  80. Baulieu E-E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(8):4279-4284.
  81. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. The journal of sexual medicine. 2009; 6(9):2579-90.
  82. Panjari, Susan R. Davis; DHEA therapy for women: effect on sexual function and wellbeing, Human Reproduction Update, Volume 13, Issue 3, 1 May 2007, Pages 239–248.
  83. Hackbert L, Heiman JR. Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women. Journal of women’s health & gender-based medicine. 2002; 11(2):155-62.
  84. Hackbert L, Heiman JR. Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women. Journal of women’s health & gender-based medicine. 2002; 11(2):155-62.
  85. Weiss EP, Villareal DT, Fontana L, Han D-H, Holloszy JO. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY). 2011;3(5):533-542.
  86. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes. 2005; 54(3):765-9.
  87. Brennan K, Huang A, Azziz R. Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertility and sterility. 2009;91(5):1848-1852. doi:10.1016/j.fertnstert.2008.02.101.
  88. Villareal DT, Holloszy JO, Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clinical endocrinology. 2000; 53(5):561-8.
  89. Ohnaka K. [Dehydroepiandrosterone(DHEA)and bone metabolism]. Clinical calcium. 2016; 26(7):987-93.
  90. Von Mühlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2008;19(5):699-707. doi:10.1007/s00198-007-0520-z.
  91. Cormier C, Souberbielle JC, Kahan A. DHEA in bone and joint diseases. Joint, bone, spine : revue du rhumatisme. 2001; 68(6):588-94.
  92. Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014; 74(11):1195-207.
  93. Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. The American Journal of Clinical Nutrition. 2009;89(5):1459-1467. doi:10.3945/ajcn.2008.27265.
  94. Luo S, Labrie C, Bélanger A, Labrie F. Effect of dehydroepiandrosterone on bone mass, serum lipids, and dimethylbenz(a)anthracene-induced mammary carcinoma in the rat. Endocrinology. 1997; 138(8):3387-94.
  95. Gordon CM, Grace E, Emans SJ, et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. The Journal of clinical endocrinology and metabolism. 2002; 87(11):4935-41.
  96. Baulieu E-E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(8):4279-4284.
  97. Ghebre MA, Hart DJ, Hakim AJ, et al. Association between DHEAS and bone loss in postmenopausal women: a 15-year longitudinal population-based study. Calcified tissue international. 2011; 89(4):295-302.
  98. Porsová-Dutoit I, Sulcová J, Stárka L. Do DHEA/DHEAS play a protective role in coronary heart disease? Physiological research. 2000; 49 Suppl 1:S43-56.
  99. Savineau JP, Marthan R, Dumas de la Roque E. Role of DHEA in cardiovascular diseases. Biochemical pharmacology. 2013; 85(6):718-26.
  100. Tivesten Å, Vandenput L, Carlzon D, et al. Dehydroepiandrosterone and its sulfate predict the 5-year risk of coronary heart disease events in elderly men. Journal of the American College of Cardiology. 2014; 64(17):1801-10.
  101. Porsová-Dutoit I, Sulcová J, Stárka L. Do DHEA/DHEAS play a protective role in coronary heart disease? Physiological research. 2000; 49 Suppl 1:S43-56.
  102. Shufelt C, Bretsky P, Almeida CM, et al. DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women: Results from the National Institutes of Health—National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). The Journal of Clinical Endocrinology and Metabolism. 2010;95(11):4985-4992. doi:10.1210/jc.2010-0143.
  103. Wu TT, Chen Y, Zhou Y, et al. Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2017; 6(5).
  104. Alzoubi A, Toba M, Abe K, et al. Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. American journal of physiology. Heart and circulatory physiology. 2013; 304(12):H1708-18.
  105. Kang J, Ge C, Yu L, Li L, Ma H. Long-Term Administration of Dehydroepiandrosterone Accelerates Glucose Catabolism via Activation of PI3K/Akt-PFK-2 Signaling Pathway in Rats Fed a High-Fat Diet. Peterson JM, ed. PLoS ONE. 2016;11(7):e0159077. doi:10.1371/journal.pone.0159077.
  106. Ostojic SM, Calleja J, Jourkesh M. Effects of short-term dehydroepiandrosterone supplementation on body composition in young athletes. The Chinese journal of physiology. 2010; 53(1):19-25.
  107. de Heredia FP, Cerezo D, Zamora S, Garaulet M. Effect of dehydroepiandrosterone on protein and fat digestibility, body protein and muscular composition in high-fat-diet-fed old rats. The British journal of nutrition. 2007; 97(3):464-70.
  108. Bromberger JT, Schott LL, Kravitz HM, et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women’s Health Across the Nation (SWAN). Archives of general psychiatry. 2010; 67(6):598-607.
  109. Available at http://drannacabeca.com/Vaginal_Atrophy.pdf.
  110. Available at https://onlinelibrary.wiley.com/doi/full/10.1111/jmwh.12628.
  111. Available at http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD011066.pub2/abstract.
  112. Barrett-Connor E, von Mühlen D, Laughlin GA, Kripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. Journal of the American Geriatrics Society. 1999; 47(6):685-91.
  113. Available at https://www.cadth.ca/media/pdf/htis/feb2015/RB0795%20DHEA%20for%20Menopause%20Final.pdf.
  114. Parsons TD, Kratz KM, Thompson E, Stanczyk FZ, Buckwalter JG. Dhea supplementation and cognition in postmenopausal women. The International journal of neuroscience. 2006; 116(2):141-55.
  115. Stangl B, Hirshman E, Verbalis J. Administration of Dehydroepiandrosterone (DHEA) Enhances Visual-Spatial Performance in Post-Menopausal Women. Behavioral neuroscience. 2011;125(5):742-752. doi:10.1037/a0025151.
  116. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.). 2016; 23(3):243-56.
  117. Morrison MF, Freeman EW, Lin H, Sammel MD. Higher DHEA-S (Dehydroepiandrosterone Sulfate) Levels are Associated with Depressive Symptoms during the Menopausal Transition: Results from the PENN Ovarian Aging Study. Archives of women’s mental health. 2011;14(5):375-382. doi:10.1007/s00737-011-0231-5.
  118. https://www.ncbi.nlm.nih.gov/pubmed/23889217https://www.ncbi.nlm.nih.gov/pubmed/23889217Fusi FM, Ferrario M, Bosisio C, Arnoldi M, Zanga L. DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013; 29(10):940-3.
  119. Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reproductive Biology and Endocrinology : RB&E. 2011;9:67. doi:10.1186/1477-7827-9-67.
  120. Naredi N, Sandeep K, Jamwal VDS, Nagraj N, Rai S. Dehydroepiandrosterone: A panacea for the ageing ovary? Medical Journal, Armed Forces India. 2015;71(3):274-277. doi:10.1016/j.mjafi.2014.12.022.
  121. Fouany MR, Sharara FI. Is there a role for DHEA supplementation in women with diminished ovarian reserve? Journal of Assisted Reproduction and Genetics. 2013;30(9):1239-1244. doi:10.1007/s10815-013-0018-x.
  122. Poli E, Manfé S, Capuzzo D, et al. DHEA pre-treated patients, poor responders to a first IVF (ICSI) cycle: clinical results. Clinical and experimental obstetrics & gynecology. 2014; 41(1):5-9.
  123. Gat I, Blanco Mejia S, Balakier H, Librach CL, Claessens A, Ryan EA. The use of coenzyme Q10 and DHEA during IUI and IVF cycles in patients with decreased ovarian reserve. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2016; 32(7):534-7.
  124. Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reproductive Biology and Endocrinology : RB&E. 2009;7:108. doi:10.1186/1477-7827-7-108.
  125. Keane KN, Hinchliffe PM, Rowlands PK, et al. DHEA Supplementation Confers No Additional Benefit to that of Growth Hormone on Pregnancy and Live Birth Rates in IVF Patients Categorized as Poor Prognosis. Frontiers in endocrinology. 2018; 9:14.
  126. Qin JC, Fan L, Qin AP. The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evidence from a meta-analysis. Journal of gynecology obstetrics and human reproduction. 2017; 46(1):1-7.
  127. Tartagni M, Cicinelli MV, Baldini D, et al. Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old. Reproductive Biology and Endocrinology : RB&E. 2015;13:18. doi:10.1186/s12958-015-0014-3.
  128. Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. The Cochrane database of systematic reviews. 2015; 1:CD011066.
  129. Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. The Journal of clinical endocrinology and metabolism. 2011; 96(6):1642-53.
  130. Labrie F, Labrie C. DHEA and intracrinology at menopause, a positive choice for evolution of the human species. Climacteric : the journal of the International Menopause Society. 2013; 16(2):205-13.
  131. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. The journal of sexual medicine. 2009; 6(9):2579-90.
  132. Lasley BL, Santoro N, Randolf JF, et al. The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity. The Journal of clinical endocrinology and metabolism. 2002; 87(8):3760-7.
  133. Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and wellbeing. Human reproduction update. ; 13(3):239-48.
  134. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. The journal of sexual medicine. 2009; 6(9):2579-90.
  135. Baulieu E-E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(8):4279-4284.
  136. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. The journal of sexual medicine. 2009; 6(9):2579-90.
  137. Panjari, Susan R. Davis; DHEA therapy for women: effect on sexual function and wellbeing, Human Reproduction Update, Volume 13, Issue 3, 1 May 2007, Pages 239–248.
  138. Hackbert L, Heiman JR. Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women. Journal of women’s health & gender-based medicine. 2002; 11(2):155-62.
  139. Baulieu E-E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(8):4279-4284.
  140. Nouveau S, Bastien P, Baldo F, de Lacharriere O. Effects of topical DHEA on aging skin: a pilot study. Maturitas. 2008; 59(2):174-81.
  141. Hennebert O, Chalbot S, Alran S, Morfin R. Dehydroepiandrosterone 7alpha-hydroxylation in human tissues: possible interference with type 1 11beta-hydroxysteroid dehydrogenase-mediated processes. The Journal of steroid biochemistry and molecular biology. 2007; 104(3-5):326-33.
  142. Villareal DT, Holloszy JO. DHEA enhances effects of weight training on muscle mass and strength in elderly women and men. American journal of physiology. Endocrinology and metabolism. 2006; 291(5):E1003-8.
  143. Chen W-C, Chen Y-M, Huang C-C, Tzeng Y-D. Dehydroepiandrosterone Supplementation Combined with Whole-Body Vibration Training Affects Testosterone Level and Body Composition in Mice. International Journal of Medical Sciences. 2016;13(10):730-740. doi:10.7150/ijms.16132.
  144. Hwang AC, Liu LK, Lee WJ, et al. Association of androgen with skeletal muscle mass and muscle function among men and women aged 50 years and older in Taiwan: results from the I-Lan longitudinal aging study. Rejuvenation research. 2013; 16(6):453-9.
  145. Dayal M, Sammel MD, Zhao J, Hummel AC, Vandenbourne K, Barnhart KT. Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of women’s health (2002). 2005; 14(5):391-400.
  146. Villareal DT, Holloszy JO. DHEA enhances effects of weight training on muscle mass and strength in elderly women and men. American journal of physiology. Endocrinology and metabolism. 2006; 291(5):E1003-8.
  147. Clore JN. Dehydroepiandrosterone and body fat. Obesity research. 1995; 3 Suppl 4:613S-616S.
  148. Libè R, Barbetta L, Dall’Asta C, et al. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. Journal of endocrinological investigation. 2004; 27(8):736-41.
  149. Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology. 1999; 53(3):590-4; discussion 594-5.
  150. Reiter WJ, Schatzl G, Märk I, Zeiner A, Pycha A, Marberger M. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urological research. 2001; 29(4):278-81.
  151. Peixoto C, Carrilho CG, Barros JA, et al. The effects of dehydroepiandrosterone on sexual function: a systematic review. Climacteric : the journal of the International Menopause Society. 2017; 20(2):129-137.
  152. Vakina TN, Shutov AM, Shalina SV, Zinov’eva EG, Kiselev IP. [Dehydroepiandrosterone and sexual function in men with chronic prostatitis]. Urologiia (Moscow, Russia : 1999).
  153. Persu C, Cauni V, Gutue S, Albu E, Jinga V, Geavlete P. Diagnosis and treatment of erectile dysfunction– a practical update. Journal of Medicine and Life. 2009;2(4):394-400.
  154. Maingat FG, Polyak MJ, Paul AM, et al. Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2013; 27(2):725-37.
  155. Maingat FG, Polyak MJ, Paul AM, et al. Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2013; 27(2):725-37.
  156. Straub RH, Schölmerich J, Zietz B. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases–substitutes of adrenal and sex hormones. Zeitschrift fur Rheumatologie. 2000; 59 Suppl 2:II/108-18.
  157. Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014; 74(11):1195-207.
  158. Alves VB, Basso PJ, Nardini V, Silva A, Chica JE, Cardoso CR. Dehydroepiandrosterone (DHEA) restrains intestinal inflammation by rendering leukocytes hyporesponsive and balancing colitogenic inflammatory responses. Immunobiology. 2016; 221(9):934-43.
  159. Andus T, Klebl F, Rogler G, Bregenzer N, Schölmerich J, Straub RH. Patients with refractory Crohn’s disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Alimentary pharmacology & therapeutics. 2003; 17(3):409-14.
  160. Petri MA, Lahita RG, Van Vollenhoven RF, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002;46(7):1820-1829.
  161. Alves VB, Basso PJ, Nardini V, Silva A, Chica JE, Cardoso CR. Dehydroepiandrosterone (DHEA) restrains intestinal inflammation by rendering leukocytes hyporesponsive and balancing colitogenic inflammatory responses. Immunobiology. 2016; 221(9):934-43.
  162. Lichte P, Pfeifer R, Werner BE, et al. Dehydroepiandrosterone modulates the inflammatory response in a bilateral femoral shaft fracture model. European Journal of Medical Research. 2014;19(1):27. doi:10.1186/2047-783X-19-27.
  163. Available at https://link.springer.com/article/10.1134/S199074781704002X.
  164. Alexaki VI, Fodelianaki G, Neuwirth A, et al. DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1/2-CREB-Jmjd3 pathway. Molecular psychiatry. 2017.
  165. Du C, Khalil MW, Sriram S. Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. Journal of immunology (Baltimore, Md. : 1950). 2001; 167(12):7094-101.
  166. Straub RH, Konecna L, Hrach S, et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin‐6 (IL‐6), and DHEA inhibits IL‐6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998; 83(6): 2012–7.
  167. Poynter ME, Daynes RA. Peroxisome proliferator‐activated receptor alpha activation modulates cellular redox status, represses nuclear factor‐kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273(49): 32 833–41.
  168. Cheng GF, Tseng J. Regulation of murine interleukin‐10 production by dehydroepiandrosterone. J Interferon Cytokine Res 2000; 20(5): 471–8.
  169. Villareal DT, Holloszy JO, Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clinical endocrinology. 2000; 53(5):561-8.
  170. Labrie F. Adrenal androgens and intracrinology. Semin Reprod Med. 2004;22:299–309.
  171. Leng SX, Cappola AR, Andersen RE, Blackman MR, Koenig K, Blair M, Walston JD. Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6 in the geriatric syndrome of frailty. Aging Clin Exp Res. 2004;16:153–157.
  172. Kahn AJ, Halloran B, Wolkowitz O, Brizendine L. Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men. J Clin Endocrinol Metab. 2002;87:1544–1549.
  173. Von Mühlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2008;19(5):699-707. doi:10.1007/s00198-007-0520-z.
  174. Villareal DT. Effects of dehydroepiandrosterone on bone mineral density: what implications for therapy? Treat Endocrinol. 2002;1:349–357.
  175. Kahn AJ, Halloran B, Wolkowitz O, Brizendine L. Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men. J Clin Endocrinol Metab. 2002;87:1544–1549.
  176. Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab. 2001;86:1968–1972.
  177. Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, LeBoff MS. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab. 2002;87:4935–4941.
  178. Arlt W, Callies F, Koehler I, van Vlijmen JC, Fassnacht M, Strasburger CJ, Seibel MJ, Huebler D, Ernst M, Oettel M, Reincke M, Schulte HM, Allolio B. Dehydroepiandroster-one supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab. 2001;86:4686–4692.
  179. Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab. 1997;82:3498–3505.
  180. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998;49:421–432.
  181. Jankowski CM, Gozansky WS, Schwartz RS, Dahl DJ, Kittelson JM, Scott SM, Van Pelt RE, Kohrt WM. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab. 2006;91:2986–2993.
  182. Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy MP, Latour F, Leaud MC, Mokrane A, Pitti-Ferrandi H, Trivalle C, de Lacharriere O, Nouveau S, Rakoto-Arison B, Souberbielle JC, Raison J, Le Bouc Y, Raynaud A, Girerd X, Forette F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA. 2000;97:4279–4284.
  183. Ohnaka K. [Dehydroepiandrosterone(DHEA)and bone metabolism]. Clinical calcium. 2016; 26(7):987-93.
  184. Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. The American Journal of Clinical Nutrition. 2009;89(5):1459-1467. doi:10.3945/ajcn.2008.27265.
  185. Jankowski CM, Gozansky WS, Schwartz RS, et al. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab 2006;91:2986–93.
  186. von Mühlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int 2008;19:699–707.
  187. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000;97:4279–84.
  188. Nair KS, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006;355:1647–59.
  189. Cormier C, Souberbielle JC, Kahan A. DHEA in bone and joint diseases. Joint, bone, spine : revue du rhumatisme. 2001; 68(6):588-94.
  190. Gordon CM, Grace E, Emans SJ, et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. The Journal of clinical endocrinology and metabolism. 2002; 87(11):4935-41.
  191. Ghebre MA, Hart DJ, Hakim AJ, et al. Association between DHEAS and bone loss in postmenopausal women: a 15-year longitudinal population-based study. Calcified tissue international. 2011; 89(4):295-302.
  192. Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. The Journal of clinical endocrinology and metabolism. 1997; 82(10):3498-505.
  193. Shufelt C, Bretsky P, Almeida CM, et al. DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women: Results from the National Institutes of Health—National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). The Journal of Clinical Endocrinology and Metabolism. 2010;95(11):4985-4992. doi:10.1210/jc.2010-0143.
  194. Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. The New England journal of medicine. 1986; 315(24):1519-24.
  195. LaCroix AZ, Yano K, Reed DM. Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation. 1992; 86(5):1529-35.
  196. Trivedi DP, Khaw KT. Dehydroepiandrosterone sulfate and mortality in elderly men and women. The Journal of clinical endocrinology and metabolism. 2001; 86(9):4171-7.
  197. Golden SH, Maguire A, Ding J, et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. American journal of epidemiology. 2002; 155(5):437-45.
  198. Johannes CB, Stellato RK, Feldman HA, Longcope C, McKinlay JB. Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women’s Health Study. Journal of clinical epidemiology. 1999; 52(2):95-103.
  199. Thijs L, Fagard R, Forette F, Nawrot T, Staessen JA. Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies. Acta cardiologica. 2003; 58(5):403-10.
  200. Bernini GP, Moretti A, Sgró M, et al. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause (New York, N.Y.). ; 8(1):43-50.
  201. Herrington DM. Dehydroepiandrosterone and coronary atherosclerosis. Annals of the New York Academy of Sciences. 1995; 774:271-80.
  202. Herrington DM, Gordon GB, Achuff SC, et al. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. Journal of the American College of Cardiology. 1990; 16(6):862-70.
  203. Bernini GP, Sgro’ M, Moretti A, et al. Endogenous androgens and carotid intimal-medial thickness in women. The Journal of clinical endocrinology and metabolism. 1999; 84(6):2008-12.
  204. Wu T, Chen Y, Zhou Y, et al. Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. 2017;6(5):e004896. doi:10.1161/JAHA.116.004896.
  205. Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014; 74(11):1195-207.
  206. Jiménez MC, Sun Q, Schürks M, et al. Low dehydroepiandrosterone sulphate is associated with increased risk of ischemic stroke among women: DHEAS and Risk of Ischemic Stroke in Women. Stroke; a journal of cerebral circulation. 2013;44(7):10.1161/STROKEAHA.111.000485. doi:10.1161/STROKEAHA.111.000485.
  207. Savineau JP, Marthan R, Dumas de la Roque E. Role of DHEA in cardiovascular diseases. Biochemical pharmacology. 2013; 85(6):718-26.
  208. Porsová-Dutoit I, Sulcová J, Stárka L. Do DHEA/DHEAS play a protective role in coronary heart disease? Physiological research. 2000; 49 Suppl 1:S43-56.
  209. Savineau JP, Marthan R, Dumas de la Roque E. Role of DHEA in cardiovascular diseases. Biochemical pharmacology. 2013; 85(6):718-26.
  210. Rabijewski M, Zgliczyński W. [Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations]. Endokrynologia Polska. ; 58(3):213-9.
  211. Wu TT, Chen Y, Zhou Y, et al. Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2017; 6(5).
  212. Lasco A, Frisina N, Morabito N, et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European journal of endocrinology. 2001; 145(4):457-61.
  213. Available at http://www.eje-online.org/content/145/4/457.long.
  214. do Vale S, Selinger L, Martins JM, et al. The relationship between dehydroepiandrosterone (DHEA), working memory and distraction–a behavioral and electrophysiological approach. PloS one. 2014; 9(8):e104869.
  215. Sripada RK, Marx CE, King AP, et al. DHEA enhances emotion regulation neurocircuits and modulates memory for emotional stimuli. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2013; 38(9):1798-807.
  216. Załuska M, Janota B. [Dehydroepiandrosteron (DHEA) in the mechanisms of stress and depression]. Psychiatria polska. ; 43(3):263-74.
  217. Nguyen TV, Gower P, Albaugh MD, et al. The developmental relationship between DHEA and visual attention is mediated by structural plasticity of cortico-amygdalar networks. Psychoneuroendocrinology. 2016; 70:122-33.
  218. De Menezes KJ, Peixoto C, Nardi AE, Carta MG, Machado S, Veras AB. Dehydroepiandrosterone, Its Sulfate and Cognitive Functions. Clinical Practice and Epidemiology in Mental Health : CP & EMH. 2016;12:24-37. doi:10.2174/1745017901612010024.
  219. Castanho T.C., Moreira P.S., Portugal-Nunes C., Novais A., Costa P.S., Palha J.A., Sousa N., Santos N.C. The role of sex and sex-related hormones in cognition, mood and well-being in older men and women. Biol. Psychol. 2014;103:158–166. doi: 10.1016/j.biopsycho.2014.08.015.
  220. Alhaj H.A., Massey A.E., McAllister-Williams R.H. Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study. Psychopharmacology (Berl.) 2006;188(4):541–551. doi: 10.1007/s00213-005-0136-y.
  221. Yamada S, Akishita M, Fukai S, et al. Effects of dehydroepiandrosterone supplementation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairment. Geriatrics & gerontology international. 2010; 10(4):280-7.
  222. Aly HF, Metwally FM, Ahmed HH. Neuroprotective effects of dehydroepiandrosterone (DHEA) in rat model of Alzheimer’s disease. Acta biochimica Polonica. 2011; 58(4):513-20.
  223. Fusi FM, Ferrario M, Bosisio C, Arnoldi M, Zanga L. DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013; 29(10):940-3.
  224. Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reproductive Biology and Endocrinology : RB&E. 2011;9:67. doi:10.1186/1477-7827-9-67.
  225. Gleicher N, Weghofer A, Barad D. Increased euploid embryos after supplementation with dehydroepiandrosterone (DHEA) in women with premature ovarian aging. Fertil Steril. 2007;88(Suppl1):S232.
  226. Gleicher N, Weghofer A, Barad DH. Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: Direct evidence from preimplantation genetic screening (PGS) Reprod Biol Endocrinol. 2010;8:140. doi: 10.1186/1477-7827-8-140.
  227. Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod Biol Endocrinol. 2009;7:108. doi: 10.1186/1477-7827-7-108.
  228. Gleicher N, Weghofer A, Barad DH. Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live birth chances in women with severely ovarian reserve. Fertil Steril. 2010;94:2824–2827. doi: 10.1016/j.fertnstert.2010.04.067.
  229. Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reproductive Biology and Endocrinology : RB&E. 2009;7:108. doi:10.1186/1477-7827-7-108.
  230. Barad DH, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril. 2005;84:756.e1-3.
  231. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod. 2006;21:2845–2949. doi: 10.1093/humrep/del254.
  232. Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet. 2007;24:629–634. doi: 10.1007/s10815-007-9178-x.
  233. Mamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone, Fertil Steril , 2009, vol. 91 (pg. 644-646)https://doi.org/10.1016/j.fertnstert.2007.11.055.
  234. Gleicher N, Barad D. Misplaced obsession with prospectively randomized studies, Reprod Biomed Online , 2010, vol. 21 (pg. 440-443)https://doi.org/10.1016/j.rbmo.2010.06.042.
  235. Gleicher N, Weghofer A,  Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone (DHEA) supplementation, Reprod Biomed Online , 2010, vol. 21 (pg. 360-365)https://doi.org/10.1016/j.rbmo.2010.04.006.
  236. Jakubowicz DJ, Beer NA, Beer RM, Nestler JE. Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women. The Journal of clinical endocrinology and metabolism. 1995; 80(11):3373-6.
  237. Zenk JL, Frestedt JL, Kuskowski MA. HUM5007, a novel combination of thermogenic compounds, and 3-acetyl-7-oxo-dehydroepiandrosterone: each increases the resting metabolic rate of overweight adults. The Journal of nutritional biochemistry. 2007; 18(9):629-34.
  238. Available at https://www.sciencedirect.com/science/article/pii/S0011393X00800260.
  239. Ostojic SM, Calleja J, Jourkesh M. Effects of short-term dehydroepiandrosterone supplementation on body composition in young athletes. The Chinese journal of physiology. 2010; 53(1):19-25.
  240. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clinical endocrinology. 1998; 49(4):421-32.
  241. Weiss EP, Villareal DT, Fontana L, Han DH, Holloszy JO. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging. 2011; 3(5):533-42.
  242. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes. 2005; 54(3):765-9.
  243. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA. 2004; 292(18):2243-8.
  244. Brahimaj A, Muka T, Kavousi M, Laven JS, Dehghan A, Franco OH. Serum dehydroepiandrosterone levels are associated with lower risk of type 2 diabetes: the Rotterdam Study. Diabetologia. 2017; 60(1):98-106.
  245. Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Schölmerich J, Falk W, Lang B. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. 1998;83:2017.
  246. Iwasaki Y, Asai M, Yoshida M, Nigawara T, Kambayashi M, Nakashima N. Dehydroepiandrosterone-sulfate inhibits nuclear factor-kB-dependent transcription in hepatocytes, possibly through antioxidant effect. J Clin Endocrinol Metab. 2004;89:3449–3454.
  247. Altman R, Motton DD, Kota RS, Rutledge JC. Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARa and NF-kB. Vascul Pharmacol. 2008;48:76–84.
  248. Gutiérrez G, Mendoza C, Zapata E, Montiel A, Reyes E, Montaño LF, López-Marure R. Dehydroepiandrosterone inhibits the TNFa-induced inflammatory response in human unbilical vein endothelial cells. Atherosclerosis. 2007;190:90–99.
  249. Kipper-Galperin M, Galilly R, Danenberg HD, Brenner T. Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor a and interleukin-6 in astrocytes. Int J Dev Neurosci. 1999;17:765–775.
  250. Du C, Khalil MW, Sriram S. Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J Immunol. 2001;167(12):7094–7101.
  251. Peters JM, Zhou Y-C, Ram PA, Lee SST, Gonzalez FJ, Waxman DJ. Peroxisome proliferator-activated receptor a required for gene induction by dehydroepiandrosterone-3b-sulfate. Mol Pharmacol. 1996;50:67–74.
  252. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor a activation modulates cellular redox status, represses nuclear factor-kB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 1998;273:32833–32841.
  253. LeFebvre P, Chinetti G, Fruchart J-C, Staels B. Sorting out the roles of PPARa in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116:571–580.
  254. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg H, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109:2197–2202.
  255. Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S, Baba S. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. DC. 1988;11:495–499.
  256. Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wójcik J, Zarnecki A, Blane G. Effects of comicronised fenofibrate on lipids and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest. 2000;30:871–878.
  257. Mussoni L, Mannucci L, Sirtori C, Pazzucconi F, Bonfardeci G, Cimminiello C, Notarbartolo A, Scafidi V, Bittolo Bon G, Alessandrini P, Nenci G, Parise P, Colombo L, Piliego T, Tremoli E. Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis. 2000;148:397–406.
  258. Okopien B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab. 2006;91:1770–1778.
  259. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptor a activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000;275:16638–16642.
  260. Furuhashi M, Ura N, Murakami H, Hyakukoku M, Yamaguchi K, Higashiura K, Shimamoto K. Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. J Endocrinol. 2002;174:321–329.
  261. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes. 2001;50:411–417.
  262. Lu M, Patsouris D, Li P, Flores-Riveros J, Frincke JM, Watkins S, Schenk S, Olefsky JM. A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats. Am J Physiol:Endocrin Metab. 2010;298:E1036–E1048.
  263. Campbell CS, Caperuto LC, Hirata AE, Araujo EP, Velloso LA, Saad MJ, Carvalho CR. The phosphatidylinositol/AKT/atypical PKC pathway is involved in the improved insulin sensitivity by DHEA in muscle and liver of rats in vivo. Life Sci. 2004;76:57–70.
  264. Sato K, Iemitsu M, Aizawa K, Ajisaka R. DHEA improves impaired activation of Akt and PKC zeta/lambda-GLUT4 pathway in skeletal muscle and improves hyperglycaemia in streptozotocin-induced diabetes rats. Acta Physiol (Oxf) 2009;197:217–225.
  265. Friess E, Trachsel L, Guldner J, Schier T, Steiger A, Holsboer F. DHEA administration increases rapid eye movement sleep and EEG power in the sigma frequency range. The American journal of physiology. 1995; 268(1 Pt 1):E107-13.
  266. Caufriez A, Leproult R, L’Hermite-Balériaux M, Kerkhofs M, Copinschi G. Effects of a 3-week dehydroepiandrosterone administration on sleep, sex steroids and multiple 24-h hormonal profiles in postmenopausal women: a pilot study. Clinical endocrinology. 2013; 79(5):716-24.
  267. Villareal DT, Holloszy JO. DHEA enhances effects of weight training on muscle mass and strength in elderly women and men. American journal of physiology. Endocrinology and metabolism. 2006; 291(5):E1003-8.
  268. Dayal M, Sammel MD, Zhao J, Hummel AC, Vandenbourne K, Barnhart KT. Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of women’s health (2002). 2005; 14(5):391-400.
  269. Hwang AC, Liu LK, Lee WJ, et al. Association of androgen with skeletal muscle mass and muscle function among men and women aged 50 years and older in Taiwan: results from the I-Lan longitudinal aging study. Rejuvenation research. 2013; 16(6):453-9.
  270. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clinical endocrinology. 1998; 49(4):421-32.
  271. Jeon S, Hur J, Kim J. DHEA Alleviates Oxidative Stress of Muscle Cells via Activation of Nrf2 Pathway. Applied biochemistry and biotechnology. 2015; 176(1):22-32.
  272. Kenny AM, Boxer RS, Kleppinger A, Brindisi J, Feinn R, Burleson JA. Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women. Journal of the American Geriatrics Society. 2010; 58(9):1707-14.
  273. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.). 2016; 23(3):243-56.
  274. Panjari M, Davis SR. Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas. 2011; 70(1):22-5.
  275. Labrie, D.F. Archer, W. Koltun, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016 Mar;23(3):243-256.
  276. Fernand Labrie, MD, PhD, David Archer, MD, Ce´line Bouchard, MD, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause: The Journal of the North American Menopause Society. 2009;16(5):907-922.
  277. Labrie, D.F. Archer, C. Bouchard, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause: The Journal of the North American Menopause Society. 2009 Sept-Oct;16(5):923-31.
  278. Barton DL, Loprinzi C, Atherton PJ, et al. Dehydroepiandrosterone for the treatment of hot flashes: a pilot study. Supportive cancer therapy. 2006; 3(2):91-7.
  279. Stomati M, Monteleone P, Casarosa E, et al. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol Endocrinol. 2000;14(5):342–363.
  280. Genazzani AR, Stomati M, Valentino V, et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric : the journal of the International Menopause Society. 2011; 14(6):661-8.
  281. Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology. 1999; 53(3):590-4; discussion 594-5.
  282. Reiter WJ, Schatzl G, Märk I, Zeiner A, Pycha A, Marberger M. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urological research. 2001; 29(4):278-81.
  283. Peixoto C, Carrilho CG, Barros JA, et al. The effects of dehydroepiandrosterone on sexual function: a systematic review. Climacteric : the journal of the International Menopause Society. 2017; 20(2):129-137.
  284. Vakina TN, Shutov AM, Shalina SV, Zinov’eva EG, Kiselev IP. [Dehydroepiandrosterone and sexual function in men with chronic prostatitis]. Urologiia (Moscow, Russia : 1999).
  285. Sundar J, Gnanasekar M. Can dehydroepiandrostenedione (DHEA) target PRL-3 to prevent colon cancer metastasis? Medical hypotheses. 2013; 80(5):595-7.
  286. Omura Y. Beneficial effects and side effects of DHEA: true anti-aging and age-promoting effects, as well as anti-cancer and cancer-promoting effects of DHEA evaluated from the effects on the normal and cancer cell telomeres and other parameters. Acupuncture & electro-therapeutics research. 2005; 30(3-4):219-61.
  287. López-Marure R, Zapata-Gómez E, Rocha-Zavaleta L, et al. Dehydroepiandrosterone inhibits events related with the metastatic process in breast tumor cell lines. Cancer biology & therapy. 2016; 17(9):915-24.
  288. López-Marure R, Gómez-Contreras P, Dillon JS: Effects of dehydroepiandrosterone on proliferation, migration and death of breast cancer cells. Eur J Pharmacol 660: 268-274, 2011.
  289. Stoll BA. Dietary supplements of dehydroepiandrosterone in relation to breast cancer risk. European journal of clinical nutrition. 1999; 53(10):771-5.
  290. Jones JA, Nguyen A, Straub M, Leidich RB, Veech RL, Wolf S. Use of DHEA in a patient with advanced prostate cancer: a case report and review. Urology. 1997; 50(5):784-8.
  291. Muscarella P, Boros LG, Fisher WE, Rink C, Melvin WS. Oral dehydroepiandrosterone inhibits the growth of human pancreatic cancer in nude mice. The Journal of surgical research. 1998; 79(2):154-7.
  292. Girón RA, Montaño LF, Escobar ML, López-Marure R. Dehydroepiandrosterone inhibits the proliferation and induces the death of HPV-positive and HPV-negative cervical cancer cells through an androgen- and estrogen-receptor independent mechanism. The FEBS journal. 2009; 276(19):5598-609.
  293. Ortega-Calderón YN, López-Marure R. Dehydroepiandrosterone inhibits proliferation and suppresses migration of human cervical cancer cell lines. Anticancer research. 2014; 34(8):4039-44.
  294. Crosbie D, Black C, McIntyre L, Royle PL, Thomas S. Dehydroepiandrosterone for systemic lupus erythematosus. The Cochrane database of systematic reviews. 2007.
  295. Sawalha AH, Kovats S. Dehydroepiandrosterone in systemic lupus erythematosus. Current rheumatology reports. 2008;10(4):286-291.
  296. van Vollenhoven RF, Engleman EG, McGuire JL. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum. 1994;37(9):1305–1310.
  297. van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol. 1998;25(2):285–289.
  298. van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum. 1995;38(12):1826–1831.
  299. van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus. 1999;8(3):181–187.
  300. Formiga F, Moga I, Nolla JM, Navarro MA, Bonnin R, Roig-Escofet D. The association of dehydroepiandrosterone sulphate levels with bone mineral density in systemic lupus erythematosus. Clin Exp Rheumatol. 1997;15(4):387–392.
  301. Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, Derksen RH. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis Rheum. 2004;50(11):3591–3595.
  302. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(11):2924–2927. [PubMed] These are two large multi-center randomized, double-blind, placebo-controlled trials that studied the effect of DHEA oral supplementation in lupus patients.
  303. Petri MA, Lahita RG, van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002;46(7):1820–1829.
  304. Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004;50(9):2858–2868.
  305. Nordmark G, Bengtsson C, Larsson A, Karlsson FA, Sturfelt G, Ronnblom L. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005;38(7):531–540.
  306. van Leuven SI, Kastelein JJ, D’Cruz DP, Hughes GR, Stroes ES. Atherogenesis in rheumatology. Lupus. 2006;15(3):117–121.
  307. Bongiovanni B, Mata-Espinosa D, D’Attilio L, et al. Effect of cortisol and/or DHEA on THP1-derived macrophages infected with Mycobacterium tuberculosis. Tuberculosis (Edinburgh, Scotland). 2015; 95(5):562-9.
  308. Buford TW, Willoughby DS. Impact of DHEA(S) and cortisol on immune function in aging: a brief review. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2008; 33(3):429-33.
  309. Loria RM, Padgett DA. Control of the immune response by DHEA and its metabolites. Rinsho byori. The Japanese journal of clinical pathology. 1998; 46(6):505-17.
  310. Loria RM, Padgett DA. Androstenediol regulates systemic resistance against lethal infections in mice. Arch Virol. 1992;127(1–4):103–115.
  311. Khorram O, Vu L, Yen SS. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. The journals of gerontology. Series A, Biological sciences and medical sciences. 1997; 52(1):M1-7.
  312. Loria RM. Immune up-regulation and tumor apoptosis by androstene steroids. Steroids. 2002;67(12):953–966.
  313. Jarrar D, Kuebler JF, Wang P, Bland KI, Chaudry IH. DHEA: a novel adjunct for the treatment of male trauma patients. Trends Mol Med. 2001;7(2):81–85.
  314. Schmidt M, Kreutz M, Loffler G, Scholmerich J, Straub RH. Conversion of dehydroepiandrosterone to downstream steroid hormones in macrophages. J Endocrinol. 2000;164(2):161–169.
  315. Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Scholmerich J, et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab. 1998;83(6):2012–2017.
  316. Daynes RA, Araneo BA, Ershler WB, Maloney C, Li GZ, Ryu SY. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol. 1993;150(12):5219–5230.
  1. Delpedro AD, Barjavel MJ, Mamdouh Z, Bakouche O. Activation of human monocytes by LPS and DHEA. J Interferon Cytokine Res. 1998;18(2):125–135.
  2. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 1998;273(49):32833–32841.
  3. Dashtaki R, Whorton AR, Murphy TM, Chitano P, Reed W, Kennedy TP. Dehydroepiandrosterone and analogs inhibit DNA binding of AP-1 and airway smooth muscle proliferation. J Pharmacol Exp Ther. 1998;285(2):876–883.
  4. Nalbandian G, Kovats S. Understanding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells. Immunol Res. 2005;31(2):91–106.
  5. Kovats S, Carreras E. Regulation of dendritic cell differentiation and function by estrogen receptor ligands. Cell Immunol. 2008.
  6. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28(5):521–574.
  7. Olsen NJ, Kovacs WJ. Effects of androgens on T and B lymphocyte development. Immunol Res. 2001;23(2–3):281–288.
  8. Schmidt M, Kreutz M, Loffler G, Scholmerich J, Straub RH. Conversion of dehydroepiandrosterone to downstream steroid hormones in macrophages. J Endocrinol. 2000;164(2):161–169.
  9. Suzuki T, Suzuki N, Daynes RA, Engleman EG. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol. 1991;61(2 Pt 1):202–211.
  10. Okabe T, Haji M, Takayanagi R, Adachi M, Imasaki K, Kurimoto F, et al. Up-regulation of high-affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. J Clin Endocrinol Metab. 1995;80(10):2993–2996.
  11. Murakawa Y, Takada S, Ueda Y, Suzuki N, Hoshino T, Sakane T. Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus. J Immunol. 1985;134(1):187–195.
  12. Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol. 2001;166(6):4216–4222.
  13. Tenbrock K, Tsokos GC. Transcriptional regulation of interleukin 2 in SLE T cells. Int Rev Immunol. 2004;23(3–4):333–345.
  14. Tenbrock K, Juang YT, Kyttaris VC, Tsokos GC. Altered signal transduction in SLE T cells. Rheumatology (Oxford) 2007;46(10):1525–1530.
  15. Suzuki T, Suzuki N, Engleman EG, Mizushima Y, Sakane T. Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE) Clin Exp Immunol. 1995;99(2):251–255.
  16. Casson PR, Andersen RN, Herrod HG, et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. American journal of obstetrics and gynecology. 1993; 169(6):1536-9.
  17. Dashtaki R, Whorton AR, Murphy TM, Chitano P, Reed W, Kennedy TP. Dehydroepiandrosterone and analogs inhibit DNA binding of AP-1 and airway smooth muscle proliferation. J Pharmacol Exp Ther. 1998;285(2):876–883.
  18. Grammer AC, Fischer R, Lee O, Zhang X, Lipsky PE. Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals. Arthritis Res Ther. 2004;6(1):28–38. [PubMed] This early study showed that oral DHEA administration prolonged survival and prevented autoantibody generation in lupus prone mice, which provided a rationale for use of DHEA in human lupus patients.
  19. Solerte SB, Fioravanti M, Vignati G, Giustina A, Cravello L, Ferrari E. Dehydroepiandrosterone sulfate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-like growth factor I. The Journal of clinical endocrinology and metabolism. 1999; 84(9):3260-7.
  20. Evans TG, Judd ME, Dowell T, Poe S, Daynes RA, Araneo BA. The use of oral dehydroepiandrosterone sulfate as an adjuvant in tetanus and influenza vaccination of the elderly. Vaccine. 1996; 14(16):1531-7.
  21. Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, Gross DJ, Friedman G. Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects. The Journal of clinical endocrinology and metabolism. 1997; 82(9):2911-4.
  22. Degelau J, Guay D, Hallgren H. The effect of DHEAS on influenza vaccination in aging adults. Journal of the American Geriatrics Society. 1997; 45(6):747-51.
  23. Choi IS, Cui Y, Koh Y-A, Lee H-C, Cho Y-B, Won Y-H. Effects of dehydroepiandrosterone on Th2 cytokine production in peripheral blood mononuclear cells from asthmatics. The Korean Journal of Internal Medicine. 2008;23(4):176-181. doi:10.3904/kjim.2008.23.4.176.
  24. Wong SY, Leung JC, Kwok T, et al. Low DHEAS levels are associated with depressive symptoms in elderly Chinese men: results from a large study. Asian Journal of Andrology. 2011;13(6):898-902. doi:10.1038/aja.2011.116.
  25. Barrett-Connor E, von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo study. J Clin Endocrinol Metab. 1999;84:573–7.
  26. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. The Journal of clinical endocrinology and metabolism. 1994; 78(6):1360-7.
  27. Peixoto C, Devicari Cheda JN, Nardi AE, Veras AB, Cardoso A. The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illnesses: a systematic review. Current drug targets. 2014; 15(9):901-14.
  28. Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biological psychiatry. 1997; 41(3):311-8.
  29. Sripada RK, Marx CE, King AP, et al. DHEA Enhances Emotion Regulation Neurocircuits and Modulates Memory for Emotional Stimuli. Neuropsychopharmacology. 2013;38(9):1798-1807. doi:10.1038/npp.2013.79.
  30. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry. 1999;45:1533–1541.
  31. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St, Clair LS, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry. 2005;62:154–162.
  32. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry. 1999;156:646–649.
  33. Alhaj HA, Massey AE, McAllister-Williams RH. Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study. Psychopharmacology (Berl) 2006;188:541–551.
  34. Hofmann SG, Ellard KK, Siegle GJ. Neurobiological correlates of cognitions in fear and anxiety: a cognitive-neurobiological information-processing model. Cogn Emot. 2012;26:282–299.
  35. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164:1476–1488.
  36. Yehuda R, Bierer LM, Pratchett LC, Pelcovitz M. Using biological markers to inform a clinically meaningful treatment response. Ann N Y Acad Sci. 2010;1208:158–163.
  37. Sageman S, Brown RP. 3-acetyl-7-oxo-dehydroepiandrosterone for healing treatment-resistant posttraumatic stress disorder in women: 5 case reports. J Clin Psychiatry. 2006;67:493–496.
  38. Berr C, Lafont S, Debuire B, Dartigues JF, Baulieu EE. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(23):13410-5.
  39. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. The Journal of clinical endocrinology and metabolism. 1994; 78(6):1360-7.
  40. Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biological psychiatry. 1997; 41(3):311-8.
  41. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biological psychiatry. 1999; 45(12):1533-41.
  42. Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R. DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology. 2000; 25(1):53-68.
  43. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. The New England journal of medicine. 1999; 341(14):1013-20.
  44. Johannsson G, Burman P, Wirén L, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. The Journal of clinical endocrinology and metabolism. 2002; 87(5):2046-52.
  45. Glick R, Jimenez X. P02.62. DHEA augmentation strategy for treatment of fatigue and depression: a case presentation. BMC Complementary and Alternative Medicine. 2012;12(Suppl 1):P118. doi:10.1186/1472-6882-12-S1-P118.
  46. Miller WL. Androgen biosynthesis from cholesterol to DHEA. Molecular and cellular endocrinology. 2002; 198(1-2):7-14.
  47. Garcés C, Cano B, Lasunción MA, et al. Dehydroepiandrosterone sulfate and high-density lipoprotein-cholesterol levels in overweight children. Obesity (Silver Spring, Md.). 2007; 15(5):1147-54.
  48. Boxer RS, Kleppinger A, Brindisi J, Feinn R, Burleson JA, Kenny AM. Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics. Age and Ageing. 2010;39(4):451-458. doi:10.1093/ageing/afq043.
  49. Rabijewski M, Zgliczyński W. [Positive effects of DHEA therapy on insulin resistance and lipids in men with angiographically verified coronary heart disease–preliminary study]. Endokrynologia Polska. ; 56(6):904-10.
  50. Nagata C, Takatsuka N, Kabuto M, Shimizu H. Association of dehydroepiandrosterone sulfate with serum HDL-cholesterol concentrations in post-menopausal Japanese women. Maturitas. 1998; 31(1):21-7.
  51. El-Alfy M, Deloche C, Azzi L, et al. Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? The British journal of dermatology. 2010; 163(5):968-76.
  52. Calvo E., Luu-The V., Morissette J. Pangenomic changes induced by DHEA in the skin of postmenopausal women. J Steroid Biochem Mol Biol. 2008;112:186–193.
  53. El-Alfy M., Deloche C., Azzi L. Skin responses to topical dehydroepiandrosterone: implications in antiaging treatment? Br J Dermatol. 2010;163:968–976.
  54. Shin M.H., Rhie G., Park C.H. Modulation of collagen metabolism by the topical application of dehydroepiandrosterone to human skin. J Invest Dermatol. 2005;124:315–323.
  55. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(8):4279-84.
  56. Daniell HW. Oral dehydroepiandrosterone might prevent frequent tears in atrophic skin: A case report. JAAD Case Reports. 2017;3(6):534-535. doi:10.1016/j.jdcr.2017.09.019.
  57. Available at https://clinicaltrials.gov/ct2/show/NCT00248989.
  58. Lee KS, Oh KY, Kim BC. Effects of dehydroepiandrosterone on collagen and collagenase gene expression by skin fibroblasts in culture. J Dermatol Sci. 2000 Jun;23(2):103-10.
  59. Calvo E, Luu-The V, Morissette J, et al. Pangenomic changes induced by DHEA in the skin of postmenopausal women. J Steroid Biochem Mol Biol. 2008 Dec;112(4-5):186-93.
  60. Jiménez MC, Sun Q, Schürks M, et al. Low dehydroepiandrosterone sulphate is associated with increased risk of ischemic stroke among women: DHEAS and Risk of Ischemic Stroke in Women. Stroke; a journal of cerebral circulation. 2013;44(7):10.1161/STROKEAHA.111.000485. doi:10.1161/STROKEAHA.111.000485.
  61. Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, Watson KO, et al. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the akt/gsk3-{beta}/nfat axis. Circulation. 2009;120:1231–1240.
  62. Blum CA, Mueller C, Schuetz P, et al. Prognostic Value of Dehydroepiandrosterone-Sulfate and Other Parameters of Adrenal Function in Acute Ischemic Stroke. Brann D, ed. PLoS ONE. 2013;8(5):e63224. doi:10.1371/journal.pone.0063224.
  63. Nguyen T-V, McCracken JT, Ducharme S, et al. Interactive Effects of Dehydroepiandrosterone and Testosterone on Cortical Thickness during Early Brain Development. The Journal of Neuroscience. 2013;33(26):10840-10848. doi:10.1523/JNEUROSCI.5747-12.2013.
Share This Page

Other Peptides

Pegylated Mechano Growth Factor

Aminophylline

Epithalon

Semax

MK-677 (IBUTAMOREN)

Success Stories

men testimonial before after

At the age of 60, I look and feel better than I ever have in my entire life! Switching my health program and hormone replacement therapy regimen over to Genemedics was one of the best decisions I’ve ever made in my life! Genemedics and Dr George have significantly improved my quality of life and also dramatically improved my overall health. I hav...
Nick Cassavetes ,60 yrs old Movie Director (“The Notebook”, “John Q”, “Alpha Dog”), Actor and Writer

See All Men’s Testimonials

Call 800-277-4041 for a Free Consultation

What to expect during your consultation:
  • Usually takes 15-30 minutes
  • Completely confidential
  • No obligation to purchase anything
  • We will discuss your symptoms along with your health and fitness goals
  • Free post-consult access for any additional questions you may have

About

Genemedics® Health Institute is a global premier institute dedicated to revolutionizing health and medicine through healthy lifestyle education, guidance and accountability in harmony with functional medicine. Our physician-supervised health programs are personally customized to help you reach your health and fitness goals while looking and feeling better than ever.

Quick Links

Our Services

 

genemedics logo

280 North Old Woodward Ave. Suite 210 Birmingham MI 48009,USA

800-277-4041

info@genemedics.com

© Copyright Genemedics Health Institute. All Rights Reserved. Privacy Policy.

Back to Top
-

Free Consultation

STEPS AWAY FROM A YOUNGER. HEALTHIER YOU!

Call 800-277-4041 for a Free Consultation

What to expect during your consultation:

  • Usually takes 15-30 minutes
  • Completely confidential
  • No obligation to purchase anything
  • We will discuss your symptoms along with your health and fitness goals
  • Free post-consult access for any additional questions you may have
Captch Background